For the year ending 2025-12-31, RNA had $162,651K increase in cash & cash equivalents over the period. -$663,760K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -684,631 |
| Depreciation | 4,151 |
| Stock-based compensation expense | 97,838 |
| Amortization of premiums and discounts on marketable securities, net | 12,524 |
| Loss on disposal of property and equipment | -140 |
| Noncash operating lease costs | 4,242 |
| Prepaid and other assets | 142,834 |
| Accounts payable | 3,799 |
| Accrued expenses and other liabilities | 90,742 |
| Operating right-of-use assets and lease liabilities, net | -2,746 |
| Deferred revenue | -8,618 |
| Net cash used in operating activities | -650,441 |
| Purchases of marketable securities | 1,106,872 |
| Proceeds from maturities of marketable securities | 1,086,222 |
| Purchases of property and equipment | 13,319 |
| Tenant improvements capitalized to right-of-use assets | 4,066 |
| Net cash used in investing activities | -38,035 |
| Proceeds from issuance of common stock in public offerings, net of issuance costs | 836,882 |
| Proceeds from issuance of common stock in private placements, net of issuance costs and allocation to deferred revenues (note 5) | 0 |
| Proceeds from issuance of pre-funded warrants in a private placement, net of issuance costs | 0 |
| Proceeds from the issuance of common stock under employee incentive equity plans | 26,517 |
| Payments for taxes related to net share settlement of equity awards | 12,409 |
| Net cash provided by financing activities | 850,990 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | 137 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 162,651 |
| Cash, cash equivalents and restricted cash at beginning of period | 222,663 |
| Cash, cash equivalents and restricted cash at end of period | 385,314 |
Avidity Biosciences, Inc. (RNA)
Avidity Biosciences, Inc. (RNA)